Association of age with the efficacy and safety of ranitidine and cimetidine in acute duodenal ulcer disease.

Age Ageing

Division of International Medical Affairs, Glaxo Group Research Limited, Uxbridge, Middlesex.

Published: November 1993

This multinational double-blind trial compared the efficacy and safety of ranitidine 300 mg nocte, 300 mg post-evening meal (pem) and cimetidine 800 mg nocte in patients with endoscopically verified duodenal ulcer disease aged < 60 years (n = 1318) and > or = 60 years (n = 354). The relative efficacy of the treatments was not dependent upon age after either 2 or 4 weeks of therapy. However, ulcer healing after 2 weeks of therapy was significantly higher in patients receiving ranitidine 300 mg pem than in those receiving cimetidine (p = 0.003) in the < 60-year group, but the difference was not significant in the > or = 60-year group. Fewer patients aged > or = 60 years on cimetidine (62%) became pain free compared with those on ranitidine (72% in both groups). Relief of epigastric pain and heartburn was related to pre-trial severity in both age groups. The incidence and type of adverse events were similar in the two age groups. It is concluded that ranitidine and cimetidine are as effective at healing duodenal ulcer and relieving ulcer symptoms in elderly as in younger patients.

Download full-text PDF

Source
http://dx.doi.org/10.1093/ageing/22.6.411DOI Listing

Publication Analysis

Top Keywords

duodenal ulcer
12
efficacy safety
8
safety ranitidine
8
ranitidine cimetidine
8
ulcer disease
8
ranitidine 300
8
aged years
8
weeks therapy
8
60-year group
8
age groups
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!